Literature DB >> 12942700

Relative value of commercial kits for ANA testing.

A S Russell1, C Johnston.   

Abstract

AIMS: We have tested the relative performance of 20 commercial ANA test kits along with that of our own laboratory to assess whether one was clearly superior.
METHODS: The sera were drawn from 3 pools that had all been pre-tested in our laboratory: patients with definite SLE; patients with non-connective tissue diseases (CTD), but where a positive FANA had been found; and normal blood donors. The tests were used in accordance with the recommendations of the specific supplier but in a routine serology laboratory.
RESULTS: Sensitivity and specificity ranged between 38 and 100%. While the negative predictive value of 4 ELISA kits was 100%, and most others were close, the HEp-2 kits were 100% in only 1 case. A positive predictive value of 100% was also seen with 1 kit.
CONCLUSION: Some of the tests are clearly better than others, but the choice may differ depending on the clinical needs, e.g. preference for a good positive or negative predictive value. However, the ELISA kits offered better results than the immunofluorescent technique. Two of them had sensitivity/specificity of > 90%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942700

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

2.  How should a district general hospital immunology service screen for anti-nuclear antibodies? An 'in-the-field' audit.

Authors:  R Hira-Kazal; P Shea-Simonds; J L Peacock; J Maher
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

3.  Antinuclear antibody testing: discordance between commercial laboratories.

Authors:  Aryeh M Abeles; Manuel Gomez-Ramirez; Micha Abeles; Shyoko Honiden
Journal:  Clin Rheumatol       Date:  2016-04-05       Impact factor: 2.980

4.  Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity.

Authors:  Ehud Paz; Muhammed Adawi; Idit Lavi; Yehuda Mussel; Reuven Mader
Journal:  Rheumatol Int       Date:  2007-02-16       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.